高尔基膜蛋白1（GOLM1）对肝细胞癌肿瘤免疫原性的影响及机制探讨

高尔基体膜蛋白1（GOLM1）是肝细胞癌（HCC）的新型血清生物标志物。以往研究表明，血清GOLM1（sGOLM1）水平在肝炎病毒感染或失代偿期肝硬化患者体内大幅度上调，并随着HCC肿瘤发生和进展而显着增加。Golm1是促进HCC生长和转移的关键癌基因。癌症的治疗效果依赖于肿瘤细胞免疫原性去触发抗肿瘤免疫应答。然而，GOLM1在抗肿瘤免疫中的功能作用尚不清楚。我们前期研究发现GOLM1缺失能够以免疫依赖性的方式抑制肿瘤生长。在这项研究中，我们期望从肿瘤免疫学的角度去深入探讨GOLM1促进癌症发展的一些新机制，从而去寻找HCC免疫疗法的新靶标。

Golgi membrane protein 1 (GOLM1) is a novel serum biomarker of hepatocellular carcinoma (HCC). Previous studies reported that serum GOLM1 (sGOLM1) level was up-regulated dramatically in patients with hepatitis virus infection or decompensated cirrhosis, which also increased enormously along with HCC tumor genesis and progression. GOLM1 is a leading gene relating to HCC growth and metastasis. The therapeutic efficacy of cancer treatments relies on tumor cell immunogenicity to trigger antitumor immune response. However, the functional role of GOLM1 in antitumor immunity is still unclear.Our previous studies found that Golm1 deficiency inhibited tumor growth in an immune-dependent fashion. In this study, we hope to demonstrate some novel mechanisms by which GOLM1 promotes cancer development from the perspective of tumor immunology and to find new target for HCC immunotherapy.